{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:49:02Z","timestamp":1782841742818,"version":"3.54.5"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/ftd.0b013e3181dcc5fb","type":"journal-article","created":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T07:38:53Z","timestamp":1270798733000},"page":"448-452","source":"Crossref","is-referenced-by-count":41,"title":["A High-Performance Liquid Chromatography Assay to Monitor the New Antiepileptic Drug Lacosamide in Patients With Epilepsy"],"prefix":"10.1097","volume":"32","author":[{"given":"Clare","family":"Greenaway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neville","family":"Ratnaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josemir W","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N","family":"Patsalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs.","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurotherapeut"},{"key":"R2-10-20210129","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures.","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"R3-10-20210129","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003495-200969040-00005","article-title":"Lacosamide: in partial onset seizures.","volume":"69","author":"Cross","year":"2009","journal-title":"Drugs"},{"key":"R4-10-20210129","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Mazurkiewicz-Beldzinska M, et al; on behalf of the SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled study.","volume":"50","author":"Halasz","year":"2009","journal-title":"Epilepsia"},{"key":"R5-10-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","article-title":"Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).","volume":"83","author":"Bialer","year":"2009","journal-title":"Epilepsy Res"},{"key":"R6-10-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nurt.2006.10.002","article-title":"Lacosamide.","volume":"4","author":"Doty","year":"2007","journal-title":"Neurotherapeutics"},{"key":"R7-10-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":"Lacosamide: a review of preclinical properties.","volume":"13","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev"},{"key":"R8-10-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1358\/dot.2008.44.1.1178468","article-title":"Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures.","volume":"44","author":"Ben-Menachem","year":"2008","journal-title":"Drugs Today"},{"key":"R10-10-20210129","first-page":"1","article-title":"Clinical perspectives on lacosamide.","volume":"1","author":"Halford","year":"2009","journal-title":"Epilpesy Curr"},{"key":"R11-10-20210129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1734-1140(09)70024-6","article-title":"Third generation antiepileptic drugs: mechanism of action, pharmacokinetics and interactions.","volume":"61","author":"Luszczki","year":"2009","journal-title":"Pharmacol Rep"},{"key":"R12-10-20210129","first-page":"4118","article-title":"Intravenous lacosamide in patients with partial-onset seizures.","volume":"48","author":"Biton","year":"2008","journal-title":"Epilepsia"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.yebeh.2008.12.009","article-title":"Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy.","volume":"14","author":"Kellinghaus","year":"2009","journal-title":"Epilepsy Behav"},{"key":"R14-10-20210129","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181dcc5fb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:37:54Z","timestamp":1620952674000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201008000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181dcc5fb","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}